| Literature DB >> 31968250 |
Etienne Paubelle1, Florence Zylbersztejn2, Thiago Trovati Maciel3, Caroline Carvalho3, Annalisa Mupo4, Meyling Cheok5, Liesbet Lieben6, Pierre Sujobert7, Justine Decroocq2, Akihiko Yokoyama8, Vahid Asnafi9, Elizabeth Macintyre9, Jérôme Tamburini7, Valérie Bardet2, Sylvie Castaigne10, Claude Preudhomme5, Hervé Dombret11, Geert Carmeliet6, Didier Bouscary7, Yelena Z Ginzburg12, Hughes de Thé13, Marc Benhamou14, Renato C Monteiro14, George S Vassiliou4, Olivier Hermine15, Ivan C Moura16.
Abstract
Vitamin D (VD) is a known differentiating agent, but the role of VD receptor (VDR) is still incompletely described in acute myeloid leukemia (AML), whose treatment is based mostly on antimitotic chemotherapy. Here, we present an unexpected role of VDR in normal hematopoiesis and in leukemogenesis. Limited VDR expression is associated with impaired myeloid progenitor differentiation and is a new prognostic factor in AML. In mice, the lack of Vdr results in increased numbers of hematopoietic and leukemia stem cells and quiescent hematopoietic stem cells. In addition, malignant transformation of Vdr-/- cells results in myeloid differentiation block and increases self-renewal. Vdr promoter is methylated in AML as in CD34+ cells, and demethylating agents induce VDR expression. Association of VDR agonists with hypomethylating agents promotes leukemia stem cell exhaustion and decreases tumor burden in AML mouse models. Thus, Vdr functions as a regulator of stem cell homeostasis and leukemic propagation.Entities:
Keywords: acute myeloid leukemia; leukemic stem cell; vitamin D receptor
Mesh:
Substances:
Year: 2020 PMID: 31968250 DOI: 10.1016/j.celrep.2019.12.055
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423